Expertise in
6
conditions

Dr. Juan Frias

Endocrinology
Office
2010 Wilshire Blvd Ste 302, 
Los Angeles, CA 
Referral may be required
Expertise in
6
conditions
Office
2010 Wilshire Blvd Ste 302, 
Los Angeles, CA 

Overview

Juan Frias is an Endocrinologist practicing medicine in Los Angeles, California.

Dr. Frias is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young, Low Blood Sugar, and Obesity.

He is actively involved in clinical research, co-authoring 114 peer reviewed articles and participating in 32 clinical trials.

Specialties

Endocrinology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Office
2010 Wilshire Blvd Ste 302, Los Angeles, CA 90057

Additional Areas of Focus

Dr. Frias has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Phase: Phase 4
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Lispro, Insulin Glargine
Study Phase: Phase 3
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drugs: LY3502970, Dulaglutide
Study Phase: Phase 2
View 9 Less Clinical Trials

114 Total Publications

Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity.
Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity.
Journal: Molecular metabolism
Published: August 12, 2025
Similar Doctors
Expertise in
43
conditions
Dr. John Carmichael
Endocrinology
Expertise in
43
conditions
Dr. John Carmichael
Endocrinology

USC Neurosurgeons Inc.

1520 San Pablo St Ste 3800, 
Los Angeles, CA 
 (96.4 miles away)
323-442-5100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Carmichael is an Endocrinologist practicing medicine in Los Angeles, California. Dr. Carmichael is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Pituitary Tumor, Hypothalamic Tumor, Acromegaly, Endoscopic Transnasal Transsphenoidal Surgery, and Endoscopy.

Expertise in
12
conditions
Dr. Shlomo Melmed
Endocrinology
Expertise in
12
conditions
Dr. Shlomo Melmed
Endocrinology

Cedars-Sinai Pituitary Center

127 S San Vicente Blvd Ste A6600, 
Los Angeles, CA 
 (103.4 miles away)
310-423-2830
Languages Spoken:
English

Shlomo Melmed is an Endocrinologist practicing medicine in Los Angeles, California. Dr. Melmed is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Acromegaly, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Acromegaloid Facial Appearance Syndrome, Pituitary Tumor, and Hormone Replacement Therapy (HRT).

Expertise in
15
conditions
Dr. Trevor Angell
Endocrinology
Expertise in
15
conditions
Dr. Trevor Angell
Endocrinology

Norris Cancer Hospital-Pasadena

625 S Fair Oaks Ave, 
Pasadena, CA 
 (99.2 miles away)
626-568-1622
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Trevor Angell is an Endocrinologist practicing medicine in Pasadena, California. He has been practicing medicine for over 17 years. Dr. Angell is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Thyroid Nodule, Thyroid Cancer, Follicular Thyroid Cancer, Papillary Thyroid Cancer, and Thyroidectomy.

Frequently Asked Questions about Dr. Juan Frias

How do I make an appointment with Dr. Juan Frias?

You can book an appointment with Dr. Juan Frias by calling their office at 213-483-1800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Juan Frias a top-rated expert for Type 2 Diabetes (T2D)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Juan Frias is classified as an Elite expert for Type 2 Diabetes (T2D), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Juan Frias specialize in?

While Dr. Juan Frias is a Endocrinology, they have specific expertise in Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young, and Low Blood Sugar. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Juan Frias participate in research or clinical trials?

Yes. Dr. Juan Frias has published 114 articles and abstracts on conditions like Type 2 Diabetes (T2D). You can view a list of Dr. Juan Frias's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Juan Frias accept my insurance?

Dr. Juan Frias accepts most major insurance plans, including Blue Cross Blue Shield and Blue Shield of California. We recommend calling the office directly at 213-483-1800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Frias's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile